Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dusquetide - Soligenix

Next Previous
Drug Profile

Dusquetide - Soligenix

Alternative Names: Dusquetide; IDR-1; Innate defense regulator-1; SGX-94; SGX-942; SGX-943; SGX-945

Latest Information Update: 25 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of British Columbia
  • Developer Soligenix; The Childrens Hospital of Philadelphia
  • Class Anti-inflammatories; Antibacterials; Antineoplastics; Peptides; Proteins
  • Mechanism of Action SQSTM1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders; Behcet's syndrome; Acute radiation syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Stomatitis
  • Phase II Behcet's syndrome
  • Preclinical Bacterial infections; Breast cancer; Infections
  • No development reported Melioidosis
  • Discontinued Lymphoproliferative disorders

Most Recent Events

  • 18 Aug 2025 Dusquetide - Soligenix receives Orphan Drug status for Behcet's syndrome in USA
  • 31 Jul 2025 Efficacy and adverse events data from phase IIa clinical trials in Behcet's syndrome released by Soligenix
  • 17 Jun 2025 Soligenix completes a phase II trial in Behcet's syndrome in Turkey (IV) (NCT06386744)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top